ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$291.77
+2.02%Jul 6, 2026, 17:45 UTC
The European Commission granted marketing authorization for AbbVie's TEPKINLY in combination with lenalidomide and rituximab for the treatment of relapsed or refractory follicular lymphoma.
Jul 3, 2026, 03:46 UTC
The U.S. FDA approved AbbVie's Skyrizi for treating pediatric plaque psoriasis and psoriatic arthritis, making it the first drug in its class approved for children under a certain weight.
Source:Jul 2, 2026, 11:55 UTC
Dingjin Biotech received FDA approval to use overseas (Taiwan) clinical data for a Phase 2 trial of OBI-858 in the US, targeting glabellar lines.
Source:Jun 30, 2026, 09:35 UTC
Genmab and AbbVie announced that their drug combination for lymphoma met the primary goal in a late-stage clinical trial.
Jun 29, 2026, 20:15 UTC
AbbVie announced positive Phase 3 results for epcoritamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
Source:Jun 29, 2026, 07:00 UTC
AbbVie received a positive CHMP opinion recommending approval of upadacitinib (RINVOQ) for non-segmental vitiligo in adults and adolescents.
Jun 26, 2026, 20:50 UTC
The U.S. FDA approved AbbVie's SKYRIZI (risankizumab-rzaa) for pediatric use in psoriatic disease.
Source:Jun 24, 2026, 14:36 UTC
AbbVie received European Union approval for Skyrizi to treat pediatric plaque psoriasis, including a new weight-based dosing option.
Source:Jun 23, 2026, 09:10 UTC
AbbVie received European Commission approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus in the European Union.
Source:Jun 23, 2026, 07:00 UTC
The European Commission approved SKYRIZI (risankizumab) for pediatric patients with moderate to severe plaque psoriasis.
Source:Jun 19, 2026, 13:51 UTC
AbbVie reported promising results from the Phase 3 CLL14 trial for chronic lymphocytic leukemia.
Source:Jun 19, 2026, 13:51 UTC
AbbVie received FDA approvals for Decnupaz and Skinvive by Juvederm.
Source:Jun 18, 2026, 20:06 UTC
AbbVie Inc. declared a quarterly cash dividend of $1.73 per share, payable on August 14, 2026, to stockholders of record on July 15, 2026.
Source:Jun 16, 2026, 12:00 UTC
Allergan Aesthetics received U.S. FDA approval for SKINVIVE by JUVÉDERM to improve neck appearance in adults over 21.
Source:Jun 3, 2026, 23:04 UTC
The UK cost-effectiveness watchdog recommended AbbVie's ovarian cancer therapy Elahere for patients with a hard-to-treat form of ovarian cancer.
Source:Jun 3, 2026, 15:06 UTC
AbbVie received European Union approval for Aquipta as an acute treatment for migraine in adults.
Source:Jun 2, 2026, 08:00 UTC
The European Commission approved AbbVie's AQUIPTA (atogepant) for acute treatment and prophylaxis of migraine in adults in the European Union.
Source:
← PreviousPage 4